Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Eric Wiedower (NPI 1154633857)

Field	Value
Entity Type	Individual
Organization	Eric Wiedower
Address	7945 Wolf River Blvd
City	Germantown
State	TN
ZIP	38138
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 10, 2010

Payer Source	Total Paid
Medicare	$2.9M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in public programs: lifetime Medicare revenue is $2.9M and there is no Medicaid billing on file, so analyses of public-program volume and risk should focus on Medicare activity rather than a dual‑payer mix. Absence of Medicaid activity indicates limited exposure to state plan payment patterns or Medicaid‑driven patient panels.

Revenue is highly concentrated in three infusible oncology agents: J9271 ($748.2K, 27.1%), J9144 ($622.4K, 22.5%), and J9299 ($457.9K, 16.6%), and the precomputed top‑3 codes account for 66.2% of this provider's total Medicare revenue. This concentration signals that a few high‑cost biologic treatments drive the bulk of Medicare payments to this clinician.

Clinical mix aligns with hematology/oncology infusion services: the top codes are oncology immunotherapies (J9271, J9144, J9299) supported by chemotherapy administration (96413), infusion management (96367), growth‑factor and supportive drugs (J0881, J2506, J1569), bone‑health therapy (J0897), and iron therapies (J1437, J1439). Together these codes indicate the practice operates as an infusion‑centric oncology service offering primary cancer therapeutics plus routine supportive care.

Competitive standing is mixed across specific agents: for J9144 the provider ranks #73 of 615 (88th percentile) which positions them as a relatively strong national participant for daratumumab while the label still classifies the volume as "typical, unremarkable." By contrast J9271 ranks #529 of 1841 (71th percentile) and J9299 ranks #180 of 505 (64th percentile), both described as "typical, unremarkable volume," indicating solid but not dominant national presence for those agents.

A small set of codes show statistically elevated participation: J0881 (62.1K claims, $124.2K revenue) ranks #37 of 1114 (97th percentile) and is labeled "notably above typical national volume," and both E/M codes 99214 (675 claims, $60.8K revenue) and 99215 (276 claims, $35.6K revenue) are described as "notably above typical national volume" at the 94th and 95th percentiles respectively. These flags suggest above‑typical utilization of darbepoetin alfa and higher complexity office visits relative to national peers, which may reflect practice focus on anemia management and complex oncology follow‑up.

The provider shows adoption of biosimilars and in‑office biologic administration: Q5107 (bevacizumab biosimilar mvasi, $82.9K) and Q5123 (rituximab biosimilar riabni, $76K) appear on the top list, with Q5107 ranking #24 of 78 (70th percentile) and Q5123 ranking #18 of 40 (56th percentile). Presence of these biosimilars in the top revenue codes indicates practical substitution of branded products with biosimilars in the infusion mix and supports an infusion‑center operational profile.

High volumes of basic labs and collection codes accompany the infusion practice: 36415 (2.5K claims, $19.9K revenue), 85025 (2.5K claims, $19.8K revenue), 80048 (2K claims, $15.9K revenue), 80076 (1.8K claims, $14.5K revenue) and 88185 (1.3K claims, $20.3K revenue) all appear among the top codes and are described as "typical, unremarkable volume" despite high national ranks on some. This pattern is consistent with in‑office phlebotomy, laboratory monitoring and diagnostic testing workflows that support ongoing chemotherapy and hematology care.

The provider has an established NPI history (enumerated 2010-07-10 (~16 years ago)), which combined with $2.9M in Medicare revenue and concentrated infusion activity suggests a mature oncology practice with sustained Medicare business. Analysts should interpret current revenue patterns as the product of a long‑standing clinical operation centered on high‑cost oncology infusions and supportive care rather than a new entrant or rapidly shifting payer mix.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

81 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,400	$40	$748.2K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	16,380	$40	$622.4K
J9299	Injection, nivolumab, 1 mg	19,080	$20	$457.9K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	62,080	$1	$124.2K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	2,870	$40	$103.3K
J0897	Injection, denosumab, 1 mg	4,800	$20	$86.4K
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	3,770	$20	$82.9K
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	2,110	$40	$76K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,900	$30	$75.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	680	$90	$60.8K

Showing 1–10 of 81

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 81 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Eric Wiedower — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

81 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	25	50	17,400	$40	$776.1K
J9299	11	20	21,010	$20	$487.5K
J9144	4	20	10,080	$40	$466.3K
J1569	15	30	3,030	$40	$175.2K
J1449	4	10	3,630	$30	$98.6K
J1437	16	20	3,700	$20	$86.3K
J0897	70	240	2,940	$20	$85K
Q5107	5	20	2,990	$20	$77.6K
Q5123	5	10	1,960	$40	$70.9K
J0881	3	70	19,050	$1	$54.4K

Showing 1–10 of 81

Related Providers

Other providers that share a Tax Identification Number (TIN) with Eric Wiedower, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Bradley Somer	TN	Hematology & Oncology Physician	$2.8M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0
Sonia Benn	MS	Hematology & Oncology Physician	$2.6M	$0

Nearby Providers

Other providers in the same ZIP code as Eric Wiedower, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Eric Wiedower — Billing Profile & Reimbursement Data

Sign up for Eric Wiedower — Billing Profile & Reimbursement Data policy alerts

Eric Wiedower — Billing Profile & Reimbursement Data

Sign up for Eric Wiedower — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References